InvestorsHub Logo
Followers 26
Posts 2868
Boards Moderated 0
Alias Born 12/05/2021

Re: antihama post# 692851

Tuesday, 05/21/2024 8:33:12 AM

Tuesday, May 21, 2024 8:33:12 AM

Post# of 700447
Thank you I appreciate your assessment

I guess what I'm trying to say is it's not comparing apples to apples.


It never is. What it as far as I have seen lately a trend among nonrevenue biotechs is that not arranging nondilutive financing and or not arranging institutions buying the stock (far) above the current market price but instead keep depending on small incremental financing from either small retail or semi pro's is lethal for the SP.

The difference in PR philosophy between Outlook and NWBO. Outlook announced the validation of their MAA to the EU back on Dec 22, 2022 w a potential approval decision in early 2024 and they got a positive CHMP opinion on March 22,2024 and stated in that PR "expected within 67 days" (still not approved I think). Of course, we found out our application was validated via the 10Q.

The positive EMA CHMP opinion is as good as approval. The only step afterwards that is the EU comission slamming a rubber stamp on the as good as approval. Therefore that cannot be compared with our application validation which does not officially say anyting yet of DCVAXL approval.

The other thing about that, well, the longer timeline for the EU.

yes the UK is much much faster in their approval process. However beats me why NWBO has not submitted a request for approval yet, after the application got validated.

Hey, wouldn't a much speedier timeline be a strong positive in how the SP will respond too?

I remain sceptic that if NWBO has not arranged a ton of non dilutive money, the SP will not get that far perhaps double where we are now are. Hopefully Linda did her job and arranged a lot of cash on condition of approval.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News